Our hosting provider will be performing UPS maintenance on Tuesday, Oct 25, 2016 between 8 AM and 5 PM PDT. SciCrunch searching services will be down during this time.

Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Antipsychotic drug effects on brain morphology in first-episode psychosis.


BACKGROUND: Pathomorphologic brain changes occurring as early as first-episode schizophrenia have been extensively described. Longitudinal studies have demonstrated that these changes may be progressive and associated with clinical outcome. This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia. OBJECTIVE: To test a priori hypotheses that olanzapine-treated patients have less change over time in whole brain gray matter volumes and lateral ventricle volumes than haloperidol-treated patients and that gray matter and lateral ventricle volume changes are associated with changes in psychopathology and neurocognition. DESIGN: Longitudinal, randomized, controlled, multisite, double-blind study. Patients treated and followed up for up to 104 weeks. Neurocognitive and magnetic resonance imaging (MRI) assessments performed at weeks 0 (baseline), 12, 24, 52, and 104. Mixed-models analyses with time-dependent covariates evaluated treatment effects on MRI end points and explored relationships between MRI, psychopathologic, and neurocognitive outcomes. SETTING: Fourteen academic medical centers (United States, 11; Canada, 1; Netherlands, 1; England, 1). PARTICIPANTS: Patients with first-episode psychosis (DSM-IV) and healthy volunteers. INTERVENTIONS: Random allocation to a conventional antipsychotic, haloperidol (2-20 mg/d), or an atypical antipsychotic, olanzapine (5-20 mg/d). MAIN OUTCOME MEASURES: Brain volume changes assessed by MRI. RESULTS: Of 263 randomized patients, 161 had baseline and at least 1 postbaseline MRI evaluation. Haloperidol-treated patients exhibited significant decreases in gray matter volume, whereas olanzapine-treated patients did not. A matched sample of healthy volunteers (n = 58) examined contemporaneously showed no change in gray matter volume. CONCLUSIONS: Patients with first-episode psychosis exhibited a significant between-treatment difference in MRI volume changes. Haloperidol was associated with significant reductions in gray matter volume, whereas olanzapine was not. Post hoc analyses suggested that treatment effects on brain volume and psychopathology of schizophrenia may be associated. The differential treatment effects on brain morphology could be due to haloperidol-associated toxicity or greater therapeutic effects of olanzapine.

Pubmed ID: 15809403


  • Lieberman JA
  • Tollefson GD
  • Charles C
  • Zipursky R
  • Sharma T
  • Kahn RS
  • Keefe RS
  • Green AI
  • Gur RE
  • McEvoy J
  • Perkins D
  • Hamer RM
  • Gu H
  • Tohen M
  • HGDH Study Group


Archives of general psychiatry

Publication Data

April 5, 2005

Associated Grants

  • Agency: NIMH NIH HHS, Id: MH 00537
  • Agency: NIMH NIH HHS, Id: MH 33127
  • Agency: NIMH NIH HHS, Id: MH 52376
  • Agency: NIMH NIH HHS, Id: MH 62157

Mesh Terms

  • Adult
  • Antipsychotic Agents
  • Benzodiazepines
  • Brain
  • Caudate Nucleus
  • Cognition Disorders
  • Female
  • Haloperidol
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Neuropsychological Tests
  • Psychiatric Status Rating Scales
  • Schizophrenia
  • Schizophrenic Psychology
  • Treatment Outcome